FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

V	as	hin	ator	ıГ	) (	?	2054	9	

Washington,	D.C.	20549	
-------------	------	-------	--

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average bur	den							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Bohen Sean					2. Issuer Name and Ticker or Trading Symbol Olema Pharmaceuticals, Inc. [ OLMA ]						elationship o ck all applica Director	able)	Perso	on(s) to Issu		
(Last) (First) (Middle) C/O OLEMA PHARMACEUTICALS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 02/01/2024						)	below)	(give title ESIDEN	T AN	Other (specification) D CEO	pecify
780 BRANNAN ST					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) SAN FRANCISCO CA 94103											)	X Form filed by One Reporting Person  Form filed by More than One Reporting  Person				ng
(City)	(S		(Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.  Parative Securities Acquired, Disposed of, or Beneficially Owned											
1. Title of Security (Instr. 3)  2. Transa Date							3. Transacti Code (Ins 8)	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		ed (A) or str. 3, 4 and 5	5. Amount of		Form: Direct I (D) or Indirect I (I) (Instr. 4)		. Nature of ndirect Beneficial Dwnership nstr. 4)	
			Table II - D	Derivativ e.g., put	e Sec s, cal	urities ls, warr	Acq ants	uired, Dis s, options	posed of converti	, or Ben ble secu	eficially ( urities)	Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	se (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	uil(S)		
Stock Option (Right to Buy)	\$15.25	02/01/2024		A		621,500		(1)	01/31/2034	Common Stock	621,500	\$0	621,50	00	D	

## **Explanation of Responses:**

1. 25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

/s/ Shane Kovacs, Attorney-in-

\*\* Signature of Reporting Person

Fact

02/05/2024

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.